The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
Abstract
Arsenic trioxide has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces complete remission in 87% of patients and molecular remission in 83% of patients. Two-year overall and relapse-free survival estimates are 63% and 49%, respectively. Treatment with arsenic trioxide may be associated with the APL differentiation syndrome, leukocytosis, and electrocardiographic abnormalities. The expanded use of arsenic trioxide in APL for postremission therapy, in conjunction with transplantation, and in patients with newly diagnosed APL is under investigation. The multiple mechanisms of action of arsenic trioxide suggest that it may have antitumor activity in malignancies other than APL and that it may be used in combination with other agents to expand its potential use. This article reviews the clinical use of arsenic trioxide to date and discusses new therapeutic strategies evolving from its diverse biologic activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Estey, E. H., Giles, F. J., Kantarjian, H., O’Brien, S., Cortes, J., Freireich, E. J., Lopez-Berestein, G., & Keating, M. (1999) · Blood · doi:10.1182/blood.v94.7.2230.419k05_2230_2235 · Cited by 105
Thomas, X., Anglaret, B., Thiebaut, A., Belhabri, A., Treille-Ritouet, D., Fiere, D., & Archimbaud, E. (1997) · Annals of Hematology · doi:10.1007/s002770050342 · Cited by 19
Cited by
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationFrom traditional Chinese medicine to rational cancer therapy
Efferth, T., Li, P. C. H., Konkimalla, V. S. B., & Kaina, B. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.001 · Cited by 528
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide
Lu, J., Chew, E.-H., & Holmgren, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701549104 · Cited by 526
Dilda, P. J., & Hogg, P. J. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.05.001 · Cited by 389
Mathews, V., George, B., Lakshmi, K. M., Viswabandya, A., Bajel, A., Balasubramanian, P., Shaji, R. V., Srivastava, V. M., Srivastava, A., & Chandy, M. (2006) · Blood · doi:10.1182/blood-2005-08-3532 · Cited by 343
Kim, J., Lee, J. J., Kim, J., Gardner, D., & Beachy, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006822107 · Cited by 304
Use of Microbial Consortia in Bioremediation of Metalloid Polluted Environments
Lashani, E., Amoozegar, M. A., Turner, R. J., & Moghimi, H. (2023) · Microorganisms · doi:10.3390/microorganisms11040891 · Cited by 44
Metadata
- Authors
- Douer, D., & Tallman, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-04-01
- Volume
- 23
- Issue
- 10
- Pages
- 2396-2410
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2064116421
- Cited by
- 236
- References
- 4
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.